Floatz logo

Zovostotug

Liposarcoma

OncoResponse, Inc.monoclonal_antibodyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Liposarcoma cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Pfizer
Phase 2B
Letrozole
Pfizer
Phase 2CCC
Enzalutamide
Pfizer
Phase 2CCC
Atirmociclib
Pfizer
Phase 2CCC
MIDAZOLAM
Pfizer
Phase 2CCC

View all 19 →

Same molecule, other indications

Zovostotug is also rated in:

neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
leiomyosarcomaDormant
CC
Indicative ·
45 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →